DYRITON SYRUP 4MG5ML

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

CHLORPHENIRAMINE MALEATE

Boleh didapati daripada:

DYNAPHARM (M) SDN BHD

INN (Nama Antarabangsa):

CHLORPHENIRAMINE MALEATE

Unit dalam pakej:

120 ml; 60 ml

Dikeluarkan oleh:

DYNAPHARM (M) SDN BHD

Risalah maklumat

DYRITON SYRUP 4MG/5ML
Chlorpheniramine Maleate (4mg/5ml)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What DYRITON SYRUP
4MG/5ML_ _is used for
2.
How DYRITON SYRUP
4MG/5ML_ _works
3.
Before you use DYRITON SYRUP
4MG/5ML
4.
How to use DYRITON SYRUP
4MG/5ML
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of DYRITON
SYRUP 4MG/5ML
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT DYRITON SYRUP 4MG/5ML
IS USED FOR
DYRITON SYRUP 4MG/5ML is used
for:
-
Palliative (relief) treatment of

hay-fever
and
vasomotor
(non-
allergic)
rhinitis
(inflammation
of
the lining inside the nose)

Allergic conjunctivitis (redness and
inflammation
of
the
thin
layer
of
tissue that covers the front of the eye)

Mild,
uncomplicated
allergic
skin
manifestations
of
urticaria
(hives)
and angioneurotic oedema (swelling
that occurs just beneath the surface
of the skin or mucous lining)

Drug sensitisation reactions (reverse
of
tolerance
which
the
escalating
effect of a medicine resulting from
repeated doses taken).
-
Amelioration (to make better or more
tolerable) of allergic reactions to blood
or
plasma,
foreign
proteins,
insect
bites and stings.
-
Relief
of
congestion
in
the
upper
respiratory
tract
associated
with
common cold or irritation arising from
dry, dusty climatic conditions.
HOW DYRITON SYRUP 4MG/5ML
WORKS
Chlorpheniramine
Maleate
is
an
antihistamine
which
reduces
allergic
symptoms.
The
antimuscarinic
action
provides
a
drying effect on the nose inner lining.
BEFORE YOU USE
DYRITON SYRUP
4MG/5ML
-
_When you must not use it _
It
should
not
be
given
to
premature
infants or newborn._ _
It
is
not
recommended
during
acute
attacks of asthma._ _
_ _
_Pregnancy and lactation _
Tell your doctor if you are pregnant,
planning
to
become
pregnant
or
breastfeeding.
Use
during
the
third
trimester
may
result
in
reactions
in
newborns.
Chlorpheniramine
maleate
may stop milk production and may be
found in breast milk. Ask your doctor for
advice be

Ciri produk

DYRITON
DESCRIPTION
CONTENT
DYRITON SYRUP 4MG/5ML
MAL19910170AZ
Dose Form :
SYRUP
Colour
:
Yellow
Flavour
:
Rose
Each 5 ml Contains:
Chlorpheniramine Maleate ..................... 4 mg
Preservatives: Methyl Paraben ............ 0.1% w/v
Propyl Paraben........... 0.01% w/v
Sodium Benzoate .......... 0.1% w/v
DYRITON TABLET 4MG
MAL19910162AZ
Dose Form :
TABLET
Colour
:
Yellow
Shape
:
Round, Flat and Scored
Each Tablet Contains:
Chlorpheniramine Maleate ..................... 4 mg
PHARMACODYNAMICS:
Chlorpheniramine Maleate is an antihistamine which acts by competing
with histamine for H1-receptor sites on effector cells. It
thereby prevents, but does not reverse, responses mediated by
histamine alone. The antimuscarinic action provides a drying
effect on the nasal mucosa.
PHARMACOKINETICS:
Chlorpheniramine Maleate is readily absorbed after oral
administration. After an oral dose, peak concentrations appear within
2
to 3 hours; the peak concentration after doses of up to 12 mg has been
variously reported as between 20 ng/ml and about 200
ng/ml. Plasma half-life after administration, has been reported as 12
to 15 hours.
It is widely distributed throughout the body tissues and appears to be
subject to enterohepatic circulation; protein binding,
about 70% bound to plasma proteins. It is extensively metabolised to
form polar and non-polar metabolites; 2 metabolites have
been identified as a result of N-demethylation and these are
mondesmethylchlorpheniramine and didesmethylchlorpheniramine.
About 35% of a dose is excreted in the urine in 48 hours; the
excretion of unchanged drug accounts for about 3 to 10% of the
dose but is increased by an increase in urinary pH and urinary flow.
Both demethylated metabolites are excreted in urine; less
than 1% of a dose is excreted in the faeces.
INDICATIONS:
For
palliative
treatment of hay-fever
and vasomotor
rhinitis; allergic
conjunctivitis; mild,
uncomplicated allergic
skin
manifestations of urticaria and angioneurotic oedema; drug
sensitisation reactions. For amelioration of allerg